the company has emphasized the potential of ALTO-300, another MDD treatment currently in Phase 2b trials. Last month, Alto ...

Favorable outcome from interim analysis of ongoing ALTO-300 Phase 2b MDD trial; topline results expected in mid-2026 – – Completed enrollment in ALTO-203 Phase 2 proof-of-concept MDD trial ...

The eight-week study tested ALTO-300, a once-daily oral drug with an undisclosed mechanism of action, in 239 patients with major depressive disorder (MDD) that was not responding well to their ...

Favorable outcome from interim analysis of ongoing ALTO-300 Phase 2b MDD trial; topline results expected in mid-2026 – – Completed enrollment in ALTO-203 Phase 2 proof-of-concept MDD trial; on track ...